| Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
| Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230] | Technology appraisal guidance | TBC |
| Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065 | Technology appraisal guidance | TBC |
| Abicipar pegol for treating wet age-related macular degeneration ID1533 | Technology appraisal guidance | TBC |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378] | Technology appraisal guidance | TBC |
| Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232 | Technology appraisal guidance | TBC |
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
| Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354 | Technology appraisal guidance | TBC |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339] | Technology appraisal guidance | |
| Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247] | Technology appraisal guidance | TBC |
| ALXN1840 for treating Wilson disease TS ID 9950 | Technology appraisal guidance | TBC |
| Alzheimer's disease (early) - gantenerumab [ID6142] | Technology appraisal guidance | TBC |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Technology appraisal guidance | |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256] | Technology appraisal guidance | |
| Amyotrophic lateral sclerosis - SAR443820 [ID6386] | Technology appraisal guidance | TBC |
| Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215] | Technology appraisal guidance | TBC |
| Asunercept for treating glioblastoma [1301] | Technology appraisal guidance | TBC |
| Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 | Technology appraisal guidance | TBC |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324] | Technology appraisal guidance | |
| Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148] | Technology appraisal guidance | TBC |
| Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203] | Technology appraisal guidance | TBC |
| Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152] | Technology appraisal guidance | TBC |
| Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |